Home
Our Expertise
Our Team
Careers
Contact Us

Also in News

EWCP have completed an investment into the UK medical device company Braidlock Ltdmore...
EWCP led a multi-million dollar Series A funding round joined by US-based investment firms GRI Fund, ASAP Ventures and prominent Angel Investors in cell therapy company, Seraxis Pte Ltd.more...
EWCP signs agreement with European Family office to jointly Manage & Fund a cancer drug delivery company.more...
EWCP provides advice to strategic investor to acquire stake in ITL Limited.more...
 

News Room



December 2012:
Scottish early stage Biopharmaceuticals company
Lamellar Biomedical raised $5.3 million in December 2012.


The company is focused on the development of proprietary mimetics of lamellar bodies as treatments for dry eye disease, radiotherapy induced xerostomia or dry mouth and diseases which affect the normal functioning of the lungs including cystic fibrosis.

Lamellar bodies are complex lipid structures which function as the bodyís method of controlling the viscosity of fluids which protect exposed surfaces of the body. These include mucous (lungs), tears (eyes) and saliva (mouth). Some applications of Lamellar Biomedicalís products will be regulated as class 2b medical devices,others as medicinal products.

Duncan Moore, Partner at East West Capital www.eastwestcap.com has been elected as Chairman of Lamellar Biomedical. East West Capital Partners have participated in the fund raise. It is expected that many of the raw materials for the manufacture of Lamellarís products will be sourced in Asia where the skills exist to manufacture high quality lipids in the volumes required by the company.

© East West Capital Partners (EWCP). All Rights Reserved. Sitemap